$8.14
0.99% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US98401F1057
Symbol
XNCR

Xencor, Inc. Stock price

$8.14
-2.46 23.21% 1M
-15.58 65.68% 6M
-14.84 64.58% YTD
-15.61 65.73% 1Y
-15.41 65.44% 3Y
-23.92 74.61% 5Y
-9.05 52.65% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.08 0.99%
ISIN
US98401F1057
Symbol
XNCR
Sector
Industry

Key metrics

Market capitalization $579.33m
Enterprise Value $331.96m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.61
P/S ratio (TTM) P/S ratio 4.55
P/B ratio (TTM) P/B ratio 0.90
Revenue growth (TTM) Revenue growth -25.88%
Revenue (TTM) Revenue $127.23m
EBIT (operating result TTM) EBIT $-166.93m
Free Cash Flow (TTM) Free Cash Flow $-168.96m
Cash position $469.57m
EPS (TTM) EPS $-3.09
P/E forward negative
P/S forward 5.26
EV/Sales forward 3.01
Short interest 16.17%
Show more

Is Xencor, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Xencor, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Xencor, Inc. forecast:

11x Buy
92%
1x Sell
8%

Analyst Opinions

12 Analysts have issued a Xencor, Inc. forecast:

Buy
92%
Sell
8%

Financial data from Xencor, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
127 127
26% 26%
100%
- Direct Costs 12 12
4% 4%
9%
115 115
28% 28%
91%
- Selling and Administrative Expenses 41 41
44% 44%
32%
- Research and Development Expense 229 229
7% 7%
180%
-155 -155
34% 34%
-122%
- Depreciation and Amortization 12 12
4% 4%
9%
EBIT (Operating Income) EBIT -167 -167
31% 31%
-131%
Net Profit -208 -208
42% 42%
-163%

In millions USD.

Don't miss a Thing! We will send you all news about Xencor, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Xencor, Inc. Stock News

Neutral
Business Wire
13 days ago
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2025 and provided a review of recent business and program updates. “Recently presented interim Phase 1 results support XmAb942 as a hi...
Neutral
Business Wire
21 days ago
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced positive interim results from its first-in-human study of XmAb942, a high-potency, extended half-life, investigational anti-TL1A antibody in clinical development for patients with inflammat...
Neutral
Business Wire
2 months ago
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Todd Simpson to its board of directors. Mr. Simpson has more than 40 years of experience in chief financial officer (CFO) roles at multiple biopharmaceutical companies an...
More Xencor, Inc. News

Company Profile

Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Head office United States
CEO Bassil Dahiyat
Employees 250
Founded 1997
Website www.xencor.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today